Overview

Study of Chimeric Monoclonal Antibodies to Shiga Toxins 1 and 2

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and efficacy of cαStx1 and cαStx2 administered concomitantly in children presenting early signs of Shiga Toxin-Producing Bacterial (STPB) Infection.
Phase:
Phase 2
Details
Lead Sponsor:
Thallion Pharmaceuticals
Collaborator:
LFB Biotechnologies, SAS
Treatments:
Antibodies
Antibodies, Monoclonal
Immunoglobulins
Shiga Toxins